CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines

U.K. pharmaceutical giant GSK said the deal gives it the rights to develop, manufacture and commercialize messenger RNA-based candidate vaccines for flu and COVID-19.

Previous post Constellations Brands’ stock up after profit tops estimates and company backs guidance
Next post What Meta and Jackson Pollock have in common — and why that matters to investors